Physician profile
Nirav Patel
NPI 1366471344
$104,653.95
in general payments reported to CMS, 2019-2025
41 companies · $2,014 in 2025
The $2,014 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,339 · 2020: $10K · 2021: $38K · 2022: $20K · 2023: $30K · 2024: $2,686 · 2025: $2,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $5,511 · Travel and Lodging: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,600.00 |
| Food and Beverage | $5,511.08 |
| Travel and Lodging | $1,048.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $93,616.19 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $2,478.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,207.66 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Boston Scientific Corporation | $1,092.60 | 2024 | |
| United Therapeutics Corporation | $945.23 | 2019-2025 | Tyvaso, Orenitram, Tyvaso |
| Ethicon INC. | $706.61 | 2022 | |
| Harmony Biosciences LLC | $567.06 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $444.13 | 2019-2025 | Xywav |
| Actelion Pharmaceuticals US, INC. | $423.99 | 2019-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $411.53 | 2021-2024 | Glassia |
| Insmed, INC. | $347.64 | 2019-2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $275.40 | 2021-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $264.58 | 2021-2025 | Acthar |
| Amgen INC. | $186.47 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $186.33 | 2020-2025 | Ofev |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $168.56 | 2024 | Purified Cortrophin Gel |
| Baxter Healthcare | $159.64 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Vest System Model 205 Acute Care |
| Merck Sharp & Dohme LLC | $137.51 | 2024-2025 | Winrevair, Keytruda |
| Medtronic, INC. | $135.80 | 2021 | |
| Pfizer INC. | $127.99 | 2019-2024 | |
| Lilly USA, LLC | $124.95 | 2025 | Zepbound |
| Philips North America LLC | $76.34 | 2019 | |
| Verona Pharma, INC. | $71.20 | 2025 | Ohtuvayre |
| Covis Pharma Gmbh | $61.92 | 2022-2023 | |
| Paratek Pharmaceuticals, INC. | $55.59 | 2019-2021 | |
| Grifols USA, LLC | $45.48 | 2024 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $37.39 | 2019-2020 | |
| Averitas Pharma INC. | $34.37 | 2025 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $32.35 | 2022 | |
| Janssen Scientific Affairs, LLC | $27.14 | 2023 | Xarelto |
| Resmed Corp | $26.86 | 2022 | |
| Mallinckrodt Enterprises LLC | $24.83 | 2019 | |
| Gilead Sciences, INC. | $23.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.29 | 2022 | |
| Ambu INC. | $19.49 | 2023 | |
| Dendreon Pharmaceuticals LLC | $17.37 | 2024 | Provenge |
| Mylan Specialty L.P. | $15.21 | 2019 | |
| Olympus America INC. | $15.01 | 2021 | |
| Pulmonx Corporation | $14.51 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Circassia INC. | $12.64 | 2019 | |
| Shionogi INC | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirav Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.